Summary: In Q1 2024, Zevra Therapeutics claimed constructive topline info from its section 2 research of KP1077 in idiopathic hypersomnia, demonstrating promising tolerance and early indicators of significant advantages. The complete results will be offered at Snooze 2024, and an … [Read more...]
Zevra Reports Positive Phase 2 Results for IH Drug Candidate
Summary: The stage 2 scientific trial of KP1077 by Zevra Therapeutics for treating idiopathic hypersomnia (IH) has yielded good leading-line effects, confirming the drug’s security and tolerability. KP1077 demonstrated important enhancements in indications these as too much … [Read more...]